SequelSEC

Humacyte, Inc. HUMA

Biological Products, (No Diagnostic Substances) · CIK 0001818382 · Fiscal year ends 1231

Revenue
$2.04M
Fiscal year ended 2025-12-31
Operating income
-$108.14M
Fiscal year ended 2025-12-31
Free cash flow
-$105.93M
Fiscal year ended 2025-12-31

Valuation, from the filing

Public float$280.30MMarket value of stock held by non-affiliates, as stated on the cover page for 2025-06-30
Float per share$1.26Float divided by shares outstanding in the same filing. A floor under the share price on that date, not the price itself.
Float / revenue137.5×A lower bound on the multiple, because affiliate holdings are excluded.
Float / equity90.2×A lower bound on the multiple, because affiliate holdings are excluded.

Every figure here is drawn from the 10-K cover page and the statements behind it, so each one traces to a filing. Public float counts only stock held by non-affiliates, which makes these floors rather than estimates: a high multiple is conclusive, a low one may mean cheap or may mean closely held. The float was measured on 2025-06-30, not today, and each multiple below it uses the figures for the fiscal year ending 2025-12-31 — the year that filing covered.

How this compares in its industry

Percentile among the Biological Products, (No Diagnostic Substances) filers on this site, highest value first. A high percentile means a large figure, which is good for a margin and not for leverage — the ranking says where the company sits, not whether that is where it should be.

MeasureReportedPercentile
Gross margin-376.1%0th
Long-term debt / equity11.40x92th
CapEx / revenue43.4%84th
FCF margin-5197.5%17th
SBC / revenue478.6%82th
Operating margin-5306.0%20th
R&D / revenue3400.5%79th
Net margin-2003.6%29th
Current ratio3.69x44th

Humacyte, Inc. (HUMA) reported revenue of $2.04M and net income of -$40.83M for the fiscal year ended 2025-12-31. This page shows 2 annual periods of income statement, balance sheet and cash flow figures normalized from Humacyte, Inc.’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Biological Products, (No Diagnostic Substances).

Income

Humacyte, Inc. income by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-31
Revenue$2.04M$0
Cost of revenue$9.70M$0
Gross profit-$7.66M$0
Operating income-$108.14M-$114.40M
Net income-$40.83M-$148.70M
Research & development$69.30M$88.60M
Weighted-average diluted sharesshares 158.16Mshares 118.48M
Pretax income-$40.83MUnavailable
Income tax expense$0$0
Diluted EPS$-0.26$-1.26
Selling, general & administrativeUnavailableUnavailable
General & administrative$31.17M$25.80M
Selling & marketingUnavailableUnavailable

Balance

Humacyte, Inc. balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-31
Cash & equivalents$50.50M$44.94M
Total assets$116.37M$137.87M
Current assets$67.80M$47.86M
Total liabilities$113.26M$190.54M
Current liabilities$18.37M$19.95M
Total equity incl. NCI$3.11M-$52.67M
Temporary (mezzanine) equityUnavailableUnavailable
Inventory$13.59M$0
Accounts receivable$441.00K$0
GoodwillUnavailableUnavailable
Long-term debt$35.44M$0
Accounts payable$5.40M$4.49M

Cash flow

Humacyte, Inc. cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-31
Operating cash flow-$105.04M-$98.12M
Capital expenditures$884.00K$1.57M
Investing cash flow-$884.00K-$1.57M
Financing cash flow$61.49M$114.18M
Net change in cash-$44.44M$14.49M
Stock-based compensation$9.75M$6.14M
Common dividends paidUnavailableUnavailable
Common share repurchasesUnavailableUnavailable
Depreciation & amortizationUnavailableUnavailable

Derived

Humacyte, Inc. derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-31
Free cash flow-$105.93M-$99.69M
Gross margin-376.1%Unavailable
Operating margin-5306.0%Unavailable
FCF margin-5197.5%Unavailable
SBC / revenue478.6%Unavailable
Current ratio3.69x2.40x
Revenue YoY growthUnavailableUnavailable
Net margin-2003.6%Unavailable
R&D / revenue3400.5%Unavailable
CapEx / revenue43.4%Unavailable
Long-term debt / equity11.40xUnavailable
Effective tax rateUnavailableUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open HUMA in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-08-12View SEC filing
10-Q · Filed 2026-05-13View SEC filing
10-K · Filed 2026-03-27View SEC filing
10-Q · Filed 2025-11-12View SEC filing
10-Q · Filed 2025-08-11View SEC filing
10-Q · Filed 2025-05-13View SEC filing

Companies in the same industry

Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.